Security key
83086J200
Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE)
CUSIP: 83086J200
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, par value $0.001
- Total 13F shares
- 24,496,645
- Total 13F value
- $196,252,371
- Share change
- +22,450,365
- Put/Call ratio
- 100%
- SEC-reported price per share
- $8.01
- Number of holders
- 62
- Value change
- +$179,861,577
- Number of buys
- 58
- Shares outstanding
- 33,945,050
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
62
Top holders
10
SKYE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Skye Bioscience, Inc. SEC filings
Skye Bioscience, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 83086J200
Recent filing periods:
Ownership snapshot
Top reported holders of SKYE - Skye Bioscience, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Versant Venture Managemen...
Disclosed value leader
Versant Venture Managemen...
Comparable rows
3/10
Latest evidence
31 Mar 2024
13F
3/4/5
Lead comparable stake: 5.9%
7 rows are not safely comparable across share classes.
Showing 1-6 of 10 holder rows.
Quick read
Versant Venture Management, LLC leads the comparable SEC ownership view at 5.9%.
3 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Versant Venture Management, LLC's linked filing trail.
Comparable ownership
Top 3
Versant Venture Management, LLC
5.9%
Financial Gravity Asset Managemen...
0%
TUCKER ASSET MANAGEMENT LLC
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Versant Venture Management, LLC |
13F
Company
|
5.9%
|
$31,400,459
2,007,702 shares
|
— | 31 Mar 2024 |
| Financial Gravity Asset Management, Inc. |
13F
Company
|
0%
|
$4,352
1,600 shares
|
— | 31 Mar 2024 |
| TUCKER ASSET MANAGEMENT LLC |
13F
Company
|
0%
|
$16
1 shares
|
— | 31 Mar 2024 |
| Versant Ventures III, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$9,386,012
501,925,802 shares
|
— | 18 Aug 2023 |
| Emerald Health Sciences Inc. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$3,167,928
169,407,901 shares
|
— | 10 Nov 2022 |
| James L. Heppell |
3/4/5
Director
|
—
class O/S missing
|
—
1,350,000 shares
|
— | 14 Sep 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
62
Shares
24,496,645
Rows available
62
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
3
Q2 2024 holders
62
Holder diff
59
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend